標(biāo)題: Titlebook: Hodgkin‘s and Non-Hodgkin‘s Lymphoma; John P. Leonard,Morton Coleman Book 2006 Springer-Verlag US 2006 Tumor.blood.bone.bone marrow.cell.d [打印本頁(yè)] 作者: Awkward 時(shí)間: 2025-3-21 19:20
書目名稱Hodgkin‘s and Non-Hodgkin‘s Lymphoma影響因子(影響力)
書目名稱Hodgkin‘s and Non-Hodgkin‘s Lymphoma影響因子(影響力)學(xué)科排名
書目名稱Hodgkin‘s and Non-Hodgkin‘s Lymphoma網(wǎng)絡(luò)公開(kāi)度
書目名稱Hodgkin‘s and Non-Hodgkin‘s Lymphoma網(wǎng)絡(luò)公開(kāi)度學(xué)科排名
書目名稱Hodgkin‘s and Non-Hodgkin‘s Lymphoma被引頻次
書目名稱Hodgkin‘s and Non-Hodgkin‘s Lymphoma被引頻次學(xué)科排名
書目名稱Hodgkin‘s and Non-Hodgkin‘s Lymphoma年度引用
書目名稱Hodgkin‘s and Non-Hodgkin‘s Lymphoma年度引用學(xué)科排名
書目名稱Hodgkin‘s and Non-Hodgkin‘s Lymphoma讀者反饋
書目名稱Hodgkin‘s and Non-Hodgkin‘s Lymphoma讀者反饋學(xué)科排名
作者: 短程旅游 時(shí)間: 2025-3-22 00:08
Book 2006eatments, and novel approaches in management of patients across the complex landscape of lymphoma subtypes. Researchers and practitioners alike will welcome this useful summary of the state of the art in this field..作者: 失敗主義者 時(shí)間: 2025-3-22 03:27
ssed in terms of interference between trajectories belonging to two different classical deflection functions. The energy dependences of the inelastic integral cross-section for curve-crossing and Demkov type transitions are also discussed. Finally the theory is reviewed in relation to a recent close作者: Mere僅僅 時(shí)間: 2025-3-22 07:26
Jonathan W. Friedberg MD,Richard I. Fisher MD and supply heat to the power station. At present, two main approaches are being investigated to achieve these objectives: magnetic confinement and inertial con- finement. In magnetic confinement research, a low-density plasma is heated by electric currents, assisted by additional heating methods su作者: 漸強(qiáng) 時(shí)間: 2025-3-22 10:23
Jia Ruan MD, PhD,John P. Leonard MDand multiply charged ions was explained and attention was given to the formation of excited states, decaying by photon or electron emission. Separate attention was given to experiments with atomic and molecular hydrogen as a target and to the scaling of electron loss and electron capture cross secti作者: 他姓手中拿著 時(shí)間: 2025-3-22 16:12 作者: fringe 時(shí)間: 2025-3-22 19:42
Richard R. Furman MD,Morton Coleman MD,Daniel Muss,John P. Leonard MDand multiply charged ions was explained and attention was given to the formation of excited states, decaying by photon or electron emission. Separate attention was given to experiments with atomic and molecular hydrogen as a target and to the scaling of electron loss and electron capture cross secti作者: 可憎 時(shí)間: 2025-3-22 23:27
Ian W. Flinn M.D., Ph.D.,Jesus G. Berdeja release of impurity elements. Thus the concentration of neutralised plasma ions and also of impurity atoms and ions is peaked close to the wall where inelastic atomic collisions between electrons and these atomic species result in localised cooling of the plasma electrons. The principal cooling pro作者: 神圣不可 時(shí)間: 2025-3-23 05:13 作者: ingenue 時(shí)間: 2025-3-23 08:40
David J. Straus MDms. In particular, it means that we must obtain better understanding of the plasma particle and energy balance, must optimize neutral beam deposition, and must control the plasma energy and particle flux to the exterior through improved limiters or with magnetic divertors. In addition, our diagnosti作者: 使閉塞 時(shí)間: 2025-3-23 12:21 作者: 野蠻 時(shí)間: 2025-3-23 13:53
Carol S. Portlock MDn. The main impurities in the plasma edge of most of the present-generation tokamaks and fusion reactor designs are carbon (≤10%), oxygen (≤5%), various metallic (and related) impurities originating from structural materials (Ti, V, Cr, Fe, Ni, Cu, Al, Mo, Mn, Mg, B, Si, Ge, Nb, Ag; with a concentra作者: 滔滔不絕地講 時(shí)間: 2025-3-23 19:56 作者: defeatist 時(shí)間: 2025-3-23 23:41 作者: 考古學(xué) 時(shí)間: 2025-3-24 02:52 作者: Lipoma 時(shí)間: 2025-3-24 10:32
Novel Small Molecules in the Treatment of Lymphomas,consider the use of new and old drugs. The panoply of new targets and drugs now becoming available for the treatment of lymphoma is truly mind-boggling. A plethora of new small molecules that target Bcl-2, mTOR, histone deactylases, and NF-kB have shown promising preclinical activity, and now promis作者: GEST 時(shí)間: 2025-3-24 12:07 作者: 商談 時(shí)間: 2025-3-24 15:18
Hodgkin‘s and Non-Hodgkin‘s Lymphoma978-0-387-29346-2Series ISSN 0927-3042 Series E-ISSN 2509-8497 作者: Atheroma 時(shí)間: 2025-3-24 20:00 作者: left-ventricle 時(shí)間: 2025-3-25 02:53
https://doi.org/10.1007/978-0-387-29346-2Tumor; blood; bone; bone marrow; cell; diagnosis; imaging; immunotherapy; lymphoma; pathogenesis; pathology; st作者: BUDGE 時(shí)間: 2025-3-25 03:41 作者: 毛細(xì)血管 時(shí)間: 2025-3-25 10:48
Cancer Treatment and Researchhttp://image.papertrans.cn/h/image/427834.jpg作者: 別名 時(shí)間: 2025-3-25 15:14
,Management of Advanced Stage Hodgkin’s Lymphoma,Hodgkin’s lymphoma (HL) is an uncommon malignancy of unknown etiology with an annual incidence in Western populations of 2–3 per 100,000 (.). On average there are 7000 new cases reported in the United States each year, distributed in a bimodal pattern with a first peak in the third decade and a second peak after the age of 50 (., .).作者: 辭職 時(shí)間: 2025-3-25 16:53
,Pathology of B-Cell Non-Hodgkin’s Lymphomas and Multiple Myeloma,L/SLL), appear to resemble more than one B-cell differentiation stage. Nevertheless, a basic understanding of B-cell differentiation stages and their associated immunophenotypic characteristics facilitates accurate diagnosis and appropriate management of B-NHLs.作者: Ointment 時(shí)間: 2025-3-25 21:11
Diffuse Large B-Cell NHL, play a role in the development of new prognostic models that may refine our ability to identify poor-risk patients. With this technology, over the next decade, it is hoped that novel therapeutic targets will be identified, allowing continued improvements in outcome for patients with this disease.作者: AVERT 時(shí)間: 2025-3-26 04:02 作者: Reservation 時(shí)間: 2025-3-26 07:16 作者: 者變 時(shí)間: 2025-3-26 10:22
,Monoclonal Antibodies in the Treatment of Non-Hodgkin’s Lymphoma,of a series of differentiation antigens, termed “cluster of differentiation” (CD) antigens. These characteristics serve as the basis for the World Health Organization (WHO) Classification of Lymphoid Neoplasms [.]. These proteins are also valuable markers for diagnosing and classifying lymphomas, as well as reliable targets for therapy.作者: asthma 時(shí)間: 2025-3-26 15:04
,Blood and Bone Marrow Transplantation for Patients with Hodgkin’s and Non-Hodgkin’s Lymphoma,) for patients with lymphoma. Initial studies were performed in refractory patients. These studies demonstrated the feasibility of this approach and ushered in more definitive trials in patients with homogenous histologies.作者: Chromatic 時(shí)間: 2025-3-26 20:15 作者: gangrene 時(shí)間: 2025-3-27 00:20
,Management of Early Stage Hodgkin’s Lymphoma,trials are attempting to reduce toxicity while continuing to achieve excellent results. This chapter will review the evolution of treatment for early stage Hodgkin lymphoma and will describe different the different approaches that have been developed.作者: acquisition 時(shí)間: 2025-3-27 02:13 作者: CHASM 時(shí)間: 2025-3-27 08:05
Lymphoma Imaging: Nuclear Medicine,d malignancies warrants better and less harmful screening strategies (.). Hence, the early identification of high-risk and low-risk patients can effectively select subpopulations that would benefit from more intensive chemotherapy protocols and can avoid unwarranted further therapy.作者: 嘮叨 時(shí)間: 2025-3-27 09:35
0927-3042 Over recent years, there has been a dramatic increase in knowledge of the biology of the lymphomas which has been accompanied by the emergence of new treatments that offer both improvements in efficacy and reduction in toxicity. Molecular profiling of tumor tissue and other new advances have led to 作者: STAT 時(shí)間: 2025-3-27 14:03
,Pathology of B-Cell Non-Hodgkin’s Lymphomas and Multiple Myeloma,atures, and biological behavior. The now widely utilized World Health Organization (WHO) classification scheme incorporates our current knowledge of the clinical and pathological features of B-cell neoplasms, and categorizes them into distinct entities (Table 1)..,. It is now generally accepted that作者: 清澈 時(shí)間: 2025-3-27 18:23 作者: Relinquish 時(shí)間: 2025-3-27 22:10
The Indolent B-Cell Lymphomas,ily recognized category of indolent lymphoma, representing about one quarter of lymphomas in the Western world..–. The incidence of follicular lymphoma is markedly lower in Asia than in the West, for unclear reasons.. Other well-defined indolent lymphomas (and their approximate percentage incidence)作者: 催眠 時(shí)間: 2025-3-28 03:44
Diffuse Large B-Cell NHL,r the past 10 years, routine incorporation of monoclonal antibody therapy in treatment regimens has favorably impacted overall survival in most subgroups of patients with DLBCL. Additionally, there has been remarkable progress in the understanding of the biological heterogeneity of this disease. His作者: 統(tǒng)治人類 時(shí)間: 2025-3-28 06:43
Mantle Cell Lymphoma: Current Concept in Biology and Treatment, CD5-positive, CD23-negative follicular mantle B cells with typical t(11; 14)(q13;q32) translocation and cyclin Dl protein over-expression. Four histological subtypes of MCL have been described which include mantle zone, nodular, diffuse, and blastoid forms. MCL commonly occurs in elderly patients w作者: 進(jìn)取心 時(shí)間: 2025-3-28 14:18
,T-Cell Non-Hogdkin’s Lymphoma,y of T-cell NHL has been documented ranging from 18.3% of NHL diagnosed in Hong Kong to 1.5% in Vancouver, British Columbia. This may in part be a reflection of increased exposure to pathogenic factors such as human T-cell leukemia virus-1 (HTLV-1) and Epstein Barr virus (EBV) in Asian nations.. T-c作者: cathartic 時(shí)間: 2025-3-28 18:26
,Monoclonal Antibodies in the Treatment of Non-Hodgkin’s Lymphoma,nally differentiate. Each lymphoma is derived from a lymphocyte that is frozen at a particular stage of development and often retains many of the immunophenotypic, morphologic, and molecular markers of the corresponding lymphocyte stage. Thus, lymphocyte development is well marked by the expression 作者: 不能妥協(xié) 時(shí)間: 2025-3-28 22:41
,Blood and Bone Marrow Transplantation for Patients with Hodgkin’s and Non-Hodgkin’s Lymphoma, chemotherapy is often limited by hematopoetic toxicity. The realization that a significantly higher dose of chemotherapy or chemoradiotherapy could be delivered to a patient by reconstituting their marrow with hematopoetic stem cells paved the way to autologous blood or marrow transplantation (ABMT作者: 責(zé)難 時(shí)間: 2025-3-29 02:27
,Vaccine Therapies for Non-Hodgkin’s Lymphomas,alities. Active immunotherapy, which attempts to harness the host’s own immune system to eradicate the malignant clone, has emerged as an important area of investigation in lymphoma. The attractiveness of this approach lies in the remarkable specificity of the adaptive immune system in recognizing t作者: 枕墊 時(shí)間: 2025-3-29 06:04 作者: 扔掉掐死你 時(shí)間: 2025-3-29 09:12
,Nodular Lymphocyte Predominant Hodgkin’s Disease, subtypes.., . Although uncommon, approximately 5% of all HD, NLPHD is important because of its unique morphologic/immunophenotypic features, as well as its clinical characteristics and evolving recommendations for therapy.作者: Neuralgia 時(shí)間: 2025-3-29 15:08
Lymphoma Imaging: Nuclear Medicine,e (HD) and aggressive subtypes of non-Hodgkin’s lymphoma (NHL). The advent of more sensitive imaging modalities have increased staging and restaging accuracy and provided more effective means to evaluate response to therapy. In the post-therapy setting, the unnecessary use of aggressive chemotherapy作者: Emg827 時(shí)間: 2025-3-29 18:01 作者: negotiable 時(shí)間: 2025-3-29 22:19
to the origin and interpretation of rainbow structure, diffraction oscillations and exchange oscillations in the potential scattering differential cross-section, and to the glory structure and symmetry oscillations in the integral cross-section. Available methods for direct inversion of the cross-s作者: 的闡明 時(shí)間: 2025-3-30 03:05 作者: Graduated 時(shí)間: 2025-3-30 07:34 作者: 伴隨而來(lái) 時(shí)間: 2025-3-30 11:27
Andrew M. Evens DO, MS,Christiane Querfeld MD,Steven T. Rosen MDocesses which give rise to enhanced losses of charged particles and energy. Losses of thermal energy occur when the magnetic field lines intercept the wall of the vessel and also because plasma ion bombardment of the wall releases radiating impurity elements due to processes such as sputtering. Neut作者: 加花粗鄙人 時(shí)間: 2025-3-30 15:15 作者: 誰(shuí)在削木頭 時(shí)間: 2025-3-30 17:03 作者: intolerance 時(shí)間: 2025-3-30 23:10
Sarah Montross MD,John M. Timmerman MDceptual scheme for providing a fusion driver for a fission-fussion hybrid system has been validated, and a demonstration of ‘break-even’ (‘D-T fusion power out = injector power in’) seems quite likely with the TFTR (Tokamak Fusion Test Reactor) device, now scheduled to begin operation in Princeton i
